NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Semler Scientific, Inc. due to allegations of violations of federal securities laws, particularly concerning undisclosed investigations by the DOJ [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Semler Scientific to contact them for discussions regarding their legal rights [1]. - A federal securities class action has been filed against Semler Scientific, with a deadline of October 28, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Semler Scientific and its executives made false or misleading statements and failed to disclose a material investigation by the DOJ related to the False Claims Act [5]. Group 2: Company Financial Impact - Semler Scientific's 2024 annual report revealed that initial settlement discussions with the DOJ began on February 11, 2025, but were ceased on the same day, indicating potential legal risks [6]. - Following the disclosure of the DOJ investigation, Semler Scientific's stock price fell over 9% on the next trading day [6]. Group 3: Whistleblower and Information Gathering - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, shareholders, and others regarding Semler Scientific's conduct [8].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Jasper Therapeutics, Inc. during the specified Class Period from November 30, 2023, to July 3, 2025, alleging misleading statements and failures in compliance with manufacturing regulations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Jasper Therapeutics lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, particularly briquilimab [5]. - It is alleged that the company's public statements were materially false and misleading, leading to investor damages when the true details were revealed [5]. Group 2: Participation Information - Investors who purchased Jasper Therapeutics securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against KBR, Inc. related to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by November 18, 2025 [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in KBR between May 6, 2025, and June 19, 2025, to discuss their legal rights [1][4]. - The complaint alleges that KBR and its executives made false or misleading statements regarding the company's partnership with HomeSafe, despite known issues with the U.S. Department of Defense's Transportation Command [6][9]. Group 2: Stock Performance Impact - Following the announcement of HomeSafe's termination of the Global Household Goods Contract, KBR's stock price fell by $3.85 per share, or 7.29%, closing at $48.93 on June 20, 2025 [7]. - On the next trading day, KBR's stock experienced an additional decline of $1.30, or 2.65%, closing at $47.63 on June 23, 2025 [7]. Group 3: Class Action Details - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [8]. - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) - ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 4, 2024, to May 23, 2025 [1]. - Allegations include that Savara Inc. made materially false and misleading statements about the MOLBREEVI BLA, specifically regarding its chemistry, manufacturing, and controls [1]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay the submission timeline previously communicated to investors [1]. Group 2: Impact on Shareholders - The delay in regulatory approval may increase the likelihood that Savara would need to raise additional capital [1]. - Shareholders are encouraged to register for the class action to monitor the case's progress and potentially seek lead plaintiff status by the deadline of November 7, 2025 [2]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to the alleged false and misleading statements that inflated the company's stock price [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violating federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 10, 2025 [2][4]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company the most, regardless of the quality of the plans [4]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [4]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to at least 2021 [5]. Group 2: Impact on Stock and Legal Proceedings - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025, amid heavy trading volume [5]. - Investors who suffered losses exceeding $75,000 between September 9, 2020, and May 1, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sable Offshore Corp. due to allegations of false and misleading statements regarding the company's oil production activities [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses exceeding $50,000 in Sable Offshore between May 19, 2025, and June 3, 2025, to contact them for legal options [1]. - A federal securities class action has been filed against Sable Offshore, with a deadline of September 26, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Sable Offshore and its executives violated federal securities laws by falsely claiming that oil production had restarted when it had not [4]. Group 2: Stock Performance - Following a court injunction against Sable's pipeline repair activities, the company's stock fell by $5.04 per share, or 15.3%, closing at $27.89 per share on May 28, 2025 [5]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3].

Core Viewpoint - A securities class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making false and misleading statements regarding its manufacturing processes and the prospects of its products, particularly briquilimab [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that purchased Jasper securities between November 30, 2023, and July 3, 2025 [1]. - The complaint alleges that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results [2]. Group 2: Allegations Against the Company - The failure to ensure compliance with manufacturing regulations increased the risk of confounding study results, adversely affecting the regulatory and commercial prospects of Jasper's products [2]. - The allegations suggest that the company's business and financial prospects, as well as the clinical and commercial prospects of briquilimab, were overstated [2]. - As a result of these issues, the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 3: Investor Information - Investors who acquired shares of Jasper are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on November 18, 2025 [3].

Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against Semler Scientific, Inc. and has set a deadline of October 28, 2025, for investors to seek the role of lead plaintiff in a federal securities class action [2][4] - The complaint alleges that Semler Scientific and its executives violated federal securities laws by making false or misleading statements and failing to disclose a material investigation by the U.S. Department of Justice regarding violations of the False Claims Act [4][5] - Following the disclosure of initial settlement discussions with the DOJ, Semler Scientific's stock fell over 9% on the next trading day, indicating a significant market reaction to the news [5] Group 2 - Investors who suffered losses exceeding $75,000 in Semler Scientific between March 10, 2021, and April 15, 2025, are encouraged to contact the law firm to discuss their legal rights [1][7] - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, highlighting its experience and capability in handling securities litigation [3]